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Objectives We hypothesized that a standardized outpatient clopidogrel desensitization protocol would be safe and effective.
Background Adverse reactions to clopidogrel are not uncommon, and affected patients must switch to ticlopidine after drug-
eluting stent placement, despite its more malignant side-effect profile, because of the risk of ischemic events
associated with premature discontinuation of dual antiplatelet therapy.
Methods Patients with suspected clopidogrel sensitivity were treated with escalating doses of clopidogrel administered
orally in solution until either a clinically significant reaction occurred or the full 75-mg tablet of clopidogrel was
tolerated. Desensitization was performed on an outpatient basis except in cases in which the subjects were inpa-
tients at the time of enrollment. Follow-up was performed at 2 to 4 weeks and 6 months after treatment. Suc-
cessful desensitization was defined as the ability to take clopidogrel 75 mg daily without a mucocutaneous,
bronchial, or anaphylactic response.
Results We enrolled 24 consecutive patients with suspected reactions to clopidogrel after DES implantation, 20 of
whom were outpatients. During desensitization, allergic-type reactions occurred in 4 patients and angina
occurred in 1 patient. Desensitization was acutely successful in all 24 patients, and by 6-month follow-up, 1 pa-
tient had persistent but improved pruritus controlled with oral antihistamines and 23 remained asymptomatic,
with only 2 patients requiring repeat desensitization.
Conclusions Clopidogrel desensitization is safe and effective, induces a sustained remission, and could be advantageous
in treating outpatients who are at-risk for premature discontinuation of dual antiplatelet therapy. (J Am Coll
Cardiol 2007;50:2039–43) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.016i
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Prug-eluting stents (DES) significantly reduce the rate of
estenosis and the need for repeat revascularization com-
ared with bare-metal stents (1,2). Premature discontinua-
ion of dual therapy with aspirin and a thienopyridine is
trongly associated with stent thrombosis and major adverse
oronary events (3). Although the optimal duration of
lopidogrel therapy has yet to be defined, recent guidelines
ecommend at least 1 year of clopidogrel after DES implan-
ation (4) because of the potential risk of thrombotic events
aused by delayed vascular healing and re-endothelialization.
otentially allergic reactions to clopidogrel have been reported
o occur in approximately 4% of patients (5), usually requiring
rug discontinuation. The alternative thienopyridine, ticlopi-
ine, is more expensive, dosed more often, and associated with
more frequent and serious adverse side-effect profile, includ-
rom the Divisions of *Allergy, Asthma & Immunology, †Interventional Cardiology,
nd ‡Cardiovascular Diseases, Scripps Clinic and Scripps Green Hospital, La Jolla,
alifornia.r
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ccepted August 20, 2007.ng blood dyscrasias (6), limiting its clinical safety and
tility.
Desensitization protocols exist for several medications (7,8).
spirin-desensitization protocols have had a significant impact
n the management of patients with cardiovascular disease (9).
e hypothesized that patients treated with DES who suffered
rom clopidogrel sensitivity could be safely and effectively
aintained on clopidogrel with a standardized outpatient
esensitization protocol.
ethods and Materials
atients. All patients screened for clopidogrel desensitiza-
ion between September 2005 and June 2006 were followed
rospectively. Patients who developed a clopidogrel reaction
fter their cardiac intervention were identified and referred
o our allergy division for a detailed history, physical, and
eview of the medical record.
There are currently no immunoglobulin-based assays for
lopidogrel sensitivity, so clinical criteria were used instead.
atients were not enrolled if more likely causes for theireactions were identified (e.g., history of intravenous [IV]-
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exposures, or if the history and
physical were clearly inconsistent
with drug sensitivity). Exclusion
criteria included exfoliative der-
matitis; toxic epidermal necroly-
sis; Stevens-Johnson rash; ana-
phylaxis; upper- or lower-airway
ompromise, including angioedema or respiratory failure; or
ther life-threatening reactions to clopidogrel or ticlopidine.
his study was approved by the Scripps Clinic institutional
eview board, and all patients provided informed consent.
lopidogrel desensitization protocol. When possible,
lopidogrel was discontinued and patients were transitioned
o ticlopidine 250 mg orally twice a daily for 5 days before
esensitization for both drug elimination and symptom
esolution. Clopidogrel desensitization was performed in an
utpatient setting, except for those patients who were
lready hospitalized for other clinical reasons. The protocol
as administered by a dedicated drug desensitization nurse
nd supervised by an allergist, who confirmed and treated
ny reactions during the protocol. The use of steroids,
ntihistamines, and antileukotrienes was stopped for 7 days
efore desensitization if feasible. Beta-blockers were held on
he day of desensitization if possible. No premedication was
dministered. Intravenous access was obtained on all pa-
ients before desensitization.
The protocol involved oral administration of an aqueous
olution containing increasing amounts of clopidogrel. The
pproach was modified from earlier, smaller studies of
lopidogrel desensitization used predominantly on inpa-
ients (10,11). Three different methods to solubilize clopi-
ogrel were used. For inpatients, finely crushed clopidogrel
as combined with a small amount of Ora-Plus compound-
ng agent (Paddock Laboratories Inc., Minneapolis, Min-
esota) then diluted with Ora-Sweet (Paddock Laboratories
nc.) to final concentrations of 0.5 and 5 mg/ml. Alterna-
ively, when Ora-Plus was unavailable, ethanol was used as
solvent to dissolve finely crushed clopidogrel and was
itrated to 0.5 and 5 mg/ml using purified drinking water.
or outpatients, analogous clopidogrel solutions were pro-
ided by a compounding pharmacy. Solution-stability in-
estigations were deemed unnecessary given the speed with
hich we used our stock solutions.
The first dose given was solvent-only, followed 30 min
ater by 0.005 mg of clopidogrel in solution. Thereafter,
oubling doses of dilute clopidogrel were given every 30 min
ntil a single 75-mg tablet was given (Table 1). All patients
ere monitored for adverse reactions. If a potentially allergic
eaction occurred, the patient was given diphenhydramine (oral
r IV) or oral cetirizine for symptom control. Once symptoms
ubsided and 30 min had elapsed since the previous dose of
lopidogrel had been given, the same dose was repeated. If no
eaction occurred, then the aforementioned protocol was con-
inued. If a reaction reoccurred, the patient was given the same
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
IV  intravenous
PCI  percutaneous
coronary interventionreatment as mentioned previously, and once the symptoms tad subsided and a minimum of 30 min had elapsed, then
he next dose of clopidogrel given was half of the provoking
ose. After desensitization, patients were instructed to con-
inue clopidogrel 75 mg daily and to follow-up with their
ardiologist within 2 weeks. Telephone follow-up was per-
ormed by the lead author at both 2 to 4 weeks and 6 months
fter desensitization to monitor for recurrent symptoms.
esults
total of 24 consecutive patients were screened for clopi-
ogrel desensitization after DES implantation. All 24 were
onsidered to have reactions likely due to clopidogrel. No
atients had to have steroids or antileukotrienes stopped.
he mean age was 62 years, 63% were male, and an average
f 2.3 DES were implanted per patient. Outpatient desen-
itization was performed in 20 patients (83%).
The most common reaction to clopidogrel was a pruritic
acular erythematous confluent rash that began either on
he face, chest, or abdomen, which then secondarily gener-
lized to cover most of the face, chest, back, abdomen, and
roximal extremities (Table 2). In 7 patients (29%), the rash
rogressed to cover the entire body, including their palms
nd soles. One patient experienced pruritus without a rash
nd one patient experienced a nonpruritic rash. Four pa-
ients experienced urticaria.
The median time between clopidogrel exposure/
ercutaneous coronary intervention (PCI) and symptom
evelopment (Table 3) was 6 days (interquartile range 3 to
days). The median time between symptom development
nd clopidogrel desensitization was 11.5 days (interquartile
ange 6 to 66 days). One patient on ticlopidine experienced
reaction to clopidogrel approximately 2.5 years before
esensitization and could not recall specifics surrounding
lopidogrel Desensitization Schedule
Table 1 Clopidogrel Desensitization Schedule
Time Dose (mg) Concentration (mg/ml) ml
8:00 AM 0 0 0.01
8:30 AM 0.005 0.5 0.01
9:00 AM 0.01 0.5 0.02
9:30 AM 0.02 0.5 0.04
10:00 AM 0.04 0.5 0.08
10:30 AM 0.08 0.5 0.16
11:00 AM 0.16 0.5 0.32
11:30 AM 0.3 0.5 0.6
12:00 PM 0.6 0.5 1.2
12:30 PM 1.2 5 0.24
1:00 PM 2.5 5 0.5
1:30 PM 5 5 1
2:00 PM 10 5 2
2:30 PM 20 5 4
3:00 PM 40 5 8
3:30 PM 75 75-mg tablet N/A
dapted from Camara and Almeda (10) and Walker et al. (11).he event aside from the characteristics of the rash.
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November 20, 2007:2039–43 Clopidogrel Desensitization After DESCutaneous reactions during desensitization occurred in 4
atients (17%) and did so at dissimilar doses (Table 4).
ruritus was the primary symptom in all of these patients.
ne of these patients developed a pruritic rash that dissi-
ated during desensitization, and 3 experienced pruritus
lone. Of the 3 patients that did not complete a 5-day
ashout of clopidogrel while receiving ticlopidine, 1 (33%)
eacted during desensitization, compared with 3 of 21
atients (14%) who completed the washout period.
Angina occurred in one patient during desensitization.
here were no electrocardiographic changes consistent with
schemia, and the patient was hemodynamically stable. The
atient’s angina resolved with one sublingual nitroglycerin
pray and desensitization was completed without further
ncident.
Desensitization was acutely successful in all 24 patients.
elephone follow-up was complete in all patients. All patients
ere still taking clopidogrel 75 mg daily at 6-month follow-up.
epeat desensitization was required and successful in 2 patients
8%). The first patient missed 3 doses of clopidogrel, which
esulted in recurrent symptoms. The second patient required
epeat desensitization 2 days after initial desensitization be-
ause of a persistent rash that eventually dissipated spontane-
usly. Two additional patients had antecedent nonallergic
ashes before enrollment. One patient had low-grade pruritus
ays of Clopidogrel Use andxtent of Initial Clopidogrel Reaction
Table 2 Days of Clopidogrel Use andExtent of Initial Clopidogrel Reaction
Patient # Days of Clopidogrel Use
Extent of Initial
Clopidogrel Reaction
1 11 Neck to hips
2 4 In ears to chest and back
3 7 Chest and back
4 10 Chest, back, and proximal extremities
5 3 Diffuse pruritus
6 9 Abdomen, chest, back, and proximal
extremities
7* 1,546 Total body, including palms and soles
8 11 Axillae, palms, and soles
9 36 Chest and back. Incidental
antecubital fossae eczema
10 20 Total body, including palms and soles
11* 6 Lower anterior abdomen
12 1 Periocular to thighs
13 Unknown Perioral
14 9 Total body, including palms and soles
15 6 Back and thighs
16 6 Chest and back
17 2 Upper chest, and back
18 5 Face, chest, and back
19 7 Chest and back to proximal thighs
20 2 Total body, including palms and soles
21 8 Face, chest, and proximal extremities
22 8 Chest to buttocks
23 9 Total body, including palms and soles
24 40 Total body, including palms and soles
Re-desensitized patients.hat was well controlled with oral antihistamines at both 4 ceeks and 6 months after desensitization. Twenty-three of the
4 patients (96%) remained entirely free of their original
lopidogrel-induced symptoms at 6-month follow-up.
iscussion
nlike previous reports (10,11), this single-center, prospec-
ive study of patients with clopidogrel sensitivity after DES
mplantation demonstrates that primarily outpatient-based
lopidogrel desensitization is feasible, safe, and effective and
nduces a sustained remission for at least 6 months. This
eries is the largest reported to date of patients receiving
lopidogrel desensitization to date.
The observation that 2 patients required repeat desensi-
ization by 6-month follow-up reflects the inherent limita-
ions of this approach to clopidogrel sensitivity. A sustained
esponse to desensitization requires excellent patient com-
liance as even brief discontinuation of the offending drug
an cause symptoms to recur once the drug is restarted.
herefore, the recurrence of clopidogrel sensitivity in pa-
ients who have been previously desensitized may serve as a
arning of noncompliance.
Premature discontinuation of dual antiplatelet therapy
as been clearly shown to be a strong, independent risk
actor for stent thrombosis, which frequently results in
-wave myocardial infarction and death. Therefore, efforts
o reduce discontinuation of clopidogrel up to 12 months
fter DES implantation are crucial (12). As observed in our
tudy, the most common period for the onset of clopidogrel
eactions was within the first 10 days after PCI. This
ime-frame coincides with the highest risk of stent throm-
osis when not treated with a thienopyridines (13); more-
ver, discontinuation of clopidogrel within 30 days after
rimary PCI with DES for ST-segment elevation myocar-
ial infarction is associated with increased rates of mortality
t 1 year (14). Outpatient clopidogrel desensitization may
herefore be an important approach to prevent discontinu-
tion and subsequent major adverse cardiac events in
lopidogrel-sensitive patients after DES.
tudy limitations. Limitations of the current study include
he nonrandomized, small, and unblinded nature inherent
o a pilot study. The potential for confounding IV contrast
nd medication reactions is also recognized. Use of antihis-
amines pre-desensitization could not be controlled for
dequately, given their ubiquitous presence in over-the-
ounter medications. The resolution of reactions with dis-
ontinuation of clopidogrel argues against other drug expo-
ures as the etiologic factors for those reactions. Also, the
bservation that all patients remained improved or asymp-
omatic post-desensitization argues that clopidogrel was
ikely the offending drug. Thus, desensitization was highly
ffective both by the end of the procedure and for up to 6
onths after it. Other reactions to DES have been reported
15), but until a specific antibody assay is developed to
iagnose clopidogrel sensitivity, it will be impossible to
ompletely exclude other agents as etiologic factors. Given
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Clopidogrel Desensitization After DES November 20, 2007:2039–43he overwhelming safety we observed with our protocol,
esensitization may be appropriate even when the offending
gent cannot be definitively identified, as the desensitization
rocedure itself may be of diagnostic utility. Moreover, the
nstantaneous and prolonged therapeutic benefit of clopi-
ogrel desensitization may obviate the need for an antibody
ssay. The clopidogrel solubilization technique differed
mong inpatients; however, this would have been unlikely to
ignificantly affect the solutions’ concentrations or absorp-
ion rates.
Previous publications speculate as to the cause of clopi-
ogrel sensitivity (10,16,17), but until the mechanism is
ound, the terms “allergy” and “hypersensitivity” should not
e used as these relate only to immunoglobulin E-mediated
eactions. Interestingly, all of our study participants reacted
o clopidogrel on their first continuous exposures to the
rug. Thus, if we are to blame antibody production for
lopidogrel sensitivity, another common antigen may exist.
imilarly, the mechanisms for drug desensitization and
List of Patients by Status, Days From ClopidogrDays From Reaction to Desensitization, and Typ
Table 3 List of Patients by Status, Days FroDays From Reaction to Desensitizat
Patient # Status
Days From Clopidogrel
Exposure/PCI to Reactio
1 Outpatient 9
2 Outpatient 1
3 Outpatient 7
4 Outpatient 1
5 Outpatient 3
6 Outpatient 6
7* Inpatient 1,546
8 Inpatient 10
9 Outpatient 33
10 Outpatient 20
11* Outpatient 3
12 Outpatient 0
13 Outpatient Unknown
14 Outpatient 8
15 Outpatient 6
16 Outpatient 6
17 Outpatient 0
18 Inpatient 5
19 Outpatient 5
20 Outpatient 2
21 Outpatient 4
22 Inpatient 7
23 Outpatient 7
24 Outpatient 30
*Re-desensitized patients.
PCI  percutaneous coronary intervention.
eactions During Desensitization
Table 4 Reactions During Desensitization
Reaction n  24 (% Total)
Pruritus alone 3 (13)
Rash alone 0
Pruritic rash 1 (4)None 20 (83)olerance-induction are unknown. It has been proposed that
f a drug reaction is immunoglobulin E-mediated, antibody-
pecific mast cell degranulation occurs and a refractory
eriod is then entered and sustained by subsequent contin-
ous drug dosing (18).
onclusions
lopidogrel desensitization appears safe and highly effective
n inducing a sustained remission in clopidogrel-sensitive
atients who require prolonged dual antiplatelet therapy
fter DES. Our data support that this approach should be
onsidered in all stable outpatients with clopidogrel sensi-
ivity who meet our inclusion and exclusion criteria to
void the potential adverse effects of ticlodipine and to
void the thrombotic risk of discontinuation of thienopy-
idine therapy.
eprint requests and correspondence: Dr. Karl F. von Tiehl,
cripps Clinic Carmel Valley, Division of Allergy, Asthma &
mmunology, 3811 Valley Centre Drive, S99, San Diego, Cali-
ornia 92130. E-mail: vontiehl.karl@scrippshealth.org.
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